Concurrent Discriminative Emission Intensity Quantification of Fexofenadine hydrochloride and Montelukast Sodium

The synergistic effect of Fexofenadine Hydrochloride an anti-histamine agent and Montelukast Sodium in treating allergies by antagonizing histamine and leukotriene prompted their use as effctive fixed dosage form combination. The current research scenario is about concurrent analysis of these drugs by spectroflourimetric method with the wavelength of excitation and emission 261nm and 287nm for Fexofenadine Hydrochloride and 392nm 487nm for Montelukast Sodium. The Calibration curves were observed to be rectilinear over the concentration ranges 20-100 mu g/mL for Fexofenadine Hydrochloride and 2-10 mu g/mL for Montelukast Sodium with good correlation coefficient in the range of 0.997 and 0.999 respectively in phosphate buffer, pH 6.8. The LOD and LOQ were found to be 0.36 mu g/mL and 2.53 mu g/mL for Fexofenadine Hydrochloride and 0.73 mu g/mL and 2.152 mu g/mL for Montelukast Sodium respectively. The assay was found to be in range of 105% for fexofenadine hydrochloride and 110% for montelukast sodium solution and %RSD values for precision and accuracy studies were found to be less than 2. The results obtained for both drugs (fexofenadine and montelukast) for various parameters were validated according to ICH guidelines. The present method can be applied for quantification of both drugs concurrently in pharmaceutical dosage forms.